Asthma Affecting Patents (Class 514/1.7)
-
Publication number: 20110152169Abstract: The invention provides methods of treating a mammal afflicted with an inflammatory disease, such as peritonitis, peritoneal adhesions or endometriosis, comprising the administration, intraperitoneal or otherwise, of a therapeutically effective amount of a SPARC polypeptide or a SPARC polypeptide-encoding isolated polynucleotide and a pharmacologic carrier.Type: ApplicationFiled: April 14, 2009Publication date: June 23, 2011Inventors: Kouros Motamed, Vuong Trieu
-
Publication number: 20110152172Abstract: Disclosed are methods of treating or preventing a pulmonary disease or disorder in a subject, the methods comprising administering an effective amount of an compound that inhibits Calmodulin Kinase II (CaMKII) activity, either directly or indirectly, thereby treating or preventing the pulmonary disease or disorder in the subject.Type: ApplicationFiled: June 22, 2010Publication date: June 23, 2011Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATIONInventors: Mark E. Anderson, Isabella M. Grumbach, Joel N. Kline
-
Publication number: 20110152174Abstract: The present invention relates to treatment of disease by inhibition of cellular secretory processes, to agents and compositions therefor, and to manufacture of those agents and compositions. The present invention relates particularly, to treatment of disease dependent upon the exocytotic activity of endocrine cells, exocrine cells, inflammatory cells, cells of the immune system, cells of the cardiovascular system and bone cells.Type: ApplicationFiled: February 7, 2011Publication date: June 23, 2011Applicant: SYNTAXIN LIMITEDInventors: Keith Alan FOSTER, John Andrew CHADDOCK, Conrad Padraig QUINN, John Robert PURKISS
-
Publication number: 20110150785Abstract: Methods of treating inflammatory conditions, disease and disorders are provided. Method include, for example, contacting or administering a sufficient amount of a LIGHT inhibitor to a subject to treat the inflammatory condition, disease or disorder.Type: ApplicationFiled: January 20, 2011Publication date: June 23, 2011Applicant: La Jolla Institute for Allergy and ImmunologyInventors: Michael Croft, Taylor Doherty, Shahram Salek-Ardakani
-
Publication number: 20110152173Abstract: This disclosure provides a multi-target fusion protein composed of a TNF-? antagonist domain and another binding domain antagonistic for a heterologous target, such as IL6, RANKL, IL7, IL17A/F, TWEAK, CSF2, IGF1, IGF2 or BLyS/APRIL, or agonistic for a heterologous target, such as IL10. The multi-specific fusion protein may also include an intervening domain that separates the binding domains and allows for dimerization. This disclosure also provides polynucleotides encoding the multi-specific fusion proteins, compositions of the fusion proteins, and methods of using the multi-specific fusion proteins and compositions.Type: ApplicationFiled: July 2, 2009Publication date: June 23, 2011Inventors: Alan Keith Lofquist, Kendall Mark Mohler, Peter Robert Baum, Peter Armstrong Thompson, Lynda Misher
-
Publication number: 20110143995Abstract: The present invention discloses novel complex molecules useful as anti-allergic agents. These complex molecules include in particular, peptidic or peptidomimetic molecules, having a first segment which is competent for cell penetration and a second segment which is able to reduce or abolish mast cell degranulation, and in particular to reduce or abolish allergy mediators such as histamine secretion from mast cells. Specific examples of peptides with the desired activity are disclosed.Type: ApplicationFiled: November 9, 2010Publication date: June 16, 2011Applicant: Ramot at Tel-Aviv University Ltd.Inventors: Ronit Eisenberg, Tamar Raz
-
Publication number: 20110142884Abstract: Provided are methods of treatment of many different diseases and disorders using micelle and sterically stabilized crystalline compounds of the invention.Type: ApplicationFiled: July 14, 2010Publication date: June 16, 2011Applicant: The Board of Trustees of the University of IllinoisInventors: Hayat Onyuksel, Israel Rubinstein
-
Publication number: 20110143994Abstract: The present invention provides improved methods and compositions for treating and preventing autoimmune and allergic diseases. More specifically the invention relates to new immuno-modulating complexes which are fusion proteins comprising mutant subunits of bacterial endotoxins, a peptide capable of binding to a specific cellular receptor, and one or more epitopes associated with an autoimmune or allergic disease.Type: ApplicationFiled: December 15, 2008Publication date: June 16, 2011Inventor: Nils Lycke
-
Publication number: 20110143992Abstract: Disclosed herein are methods and compositions related to GHS-R antagonists.Type: ApplicationFiled: February 13, 2007Publication date: June 16, 2011Inventors: Dennis Taub, Vishwa Deep Dixit
-
Publication number: 20110123530Abstract: Compositions, kits and methods for treating and diagnosing subtypes of asthma patients are provided. Also provided are methods for identifying effective asthma therapeutic agents and predicting responsiveness to asthma therapeutic agents.Type: ApplicationFiled: March 31, 2009Publication date: May 26, 2011Inventors: Joseph R. Arron, John V. Fahy, Barmak Modrek, Prescott Woodruff
-
Patent number: 7947648Abstract: The present invention relates generally to methods and compounds for treating pulmonary disorders, and more specifically to the inhalation administration and use of hIL-4 mutant proteins to treat asthma.Type: GrantFiled: January 11, 2007Date of Patent: May 24, 2011Assignee: Aerovance, Inc.Inventors: Jeffrey Tepper, Adrian Tomkinson
-
Publication number: 20110117106Abstract: Calpains target junctional components that normally seal the epithelium, forming tight junctions. This selective targeting by calpains facilitates the transmigration of leukocytes across the epithelium and into tissue spaces where they can cause inflammation. The present disclosure provides methods of using calpain inhibitors to prevent epithelial junction reorganization such that leukocyte transmigration is inhibited and accordingly, inflammation reduced or prevented. These methods can at least be used to reduce respiratory inflammation by preventing leukocyte accumulation in pulmonary airways.Type: ApplicationFiled: March 6, 2009Publication date: May 19, 2011Inventor: Alice Prince
-
Publication number: 20110112011Abstract: Disclosed are pharmaceutical compositions containing, as active ingredients, a mixture of a corticosteroid and a kinin B2 receptor antagonist. Said compositions have proved particularly effective, especially in the treatment of inflammatory disorders such as asthma, ophthalmic or dermatological disorders and, above all, as regards the joints, arthritis.Type: ApplicationFiled: July 3, 2009Publication date: May 12, 2011Applicant: ISTITUTO LUSO FARMACO D'ITALIA S.P.A.Inventors: Sandro Giuliani, Carlo Alberto Maggi
-
Publication number: 20110104217Abstract: Disclosed are peptide ligands for G-protein coupled receptors that are useful for treating disorders associated with G-protein coupled receptor activation.Type: ApplicationFiled: December 14, 2010Publication date: May 5, 2011Inventors: Yossi Cohen, Ronen Shemesh, Amir Toporik, Zurit Levine, Assaf Wool, Dvir Dahary, Iris Hecht, Galit Rotman, Michal Ayalon-Soffer
-
Publication number: 20110104263Abstract: The disclosure provides methods and compositions useful for treating claudin-4 associated disorders including cell proliferative disorders. The disclosure also provide claudin-family binding peptides useful in the methods of the disclosure.Type: ApplicationFiled: April 30, 2009Publication date: May 5, 2011Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: David D. Lo, Jun Ling, Mary M. Hamer, Thejani Rajapaksa
-
Publication number: 20110107443Abstract: This invention relates to novel protein transduction domains (PTDs) derived from secretory leukocyte protease inhibitor (SLPI). SLPI-derived PTDs are able to deliver cargo moieties in vivo and in vitro into the cytoplasm and nucleus of a host cell. The invention also relates to a transduction complex comprising one or more SLPI-derived PTDs linked or fused to one or more cargo moieties, which may comprise, for example, proteins, nucleic acids, lipids, carbohydrates, small molecules and other chemical compounds. The invention also relates to the manufacture of SLPI-derived PTDs, complexes comprising them; compositions comprising SLPI-derived PTDs or complexes; and utilization of SLPI-derived PTDs or complexes comprising them for therapeutic, diagnostic and research methods involving delivery of heterologous molecules across cellular membranes, and especially, across nuclear membranes.Type: ApplicationFiled: October 2, 2008Publication date: May 5, 2011Inventors: Marie T. Filbin, Sari Hannila
-
Publication number: 20110098212Abstract: A novel cytokine, U83A, is described, as are variant forms of the cytokine, having a wide range of agonistic and antagonistic activity against chemokine receptors. Uses of the chemokine in treatment of a range of diseases, including cancers and HIV/AIDS, are described.Type: ApplicationFiled: May 25, 2006Publication date: April 28, 2011Inventors: Ursula Gompels, Julie Catusse, David Dewin
-
Patent number: 7931898Abstract: The invention provides methods and compositions for inhibiting binding of IgE to a high affinity receptor. The methods and compositions are useful in the treatment of allergic diseases and allergy symptoms in mammals.Type: GrantFiled: May 9, 2008Date of Patent: April 26, 2011Assignee: IDEXX Laboratories, Inc.Inventors: Eugene Regis Krah, III, Robert Lawton
-
Publication number: 20110082073Abstract: The present invention relates to isolated Cpn10 polypeptides possessing an increased affinity for a PRR ligand compared to Ala Cpn10 polypeptide. In a further embodiment, the present invention also relates to modified chaperonin 10 polypeptides, and to nucleic acids encoding the same and to compositions comprising such polypeptides and uses thereof.Type: ApplicationFiled: April 9, 2009Publication date: April 7, 2011Applicant: CBIO LIMITEDInventors: Dean Jason Naylor, Richard James Brown, Christopher Bruce Howard, Christopher John De Bakker, Linda Alisson Ward, Jeanette Elizabeth Stok, Andrew Leigh James, Daniel Scott Lambert, Kylie Jane Ralston, Walter Rene Antonius Van Heumen
-
Publication number: 20110081344Abstract: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for soluble zcytor11 receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides and antibodies can also be used to block TIF activity in vitro and in vivo, and may be used in conjunction with TIF and other cytokines to selectively stimulate the immune system. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.Type: ApplicationFiled: November 10, 2010Publication date: April 7, 2011Inventors: Wayne R. Kindsvogel, Stavros Topouzis
-
Publication number: 20110077191Abstract: The present invention provides novel peptides that inhibit and/or reduce the opening of mammalian tight junctions, i.e. peptide tight junction antagonists. The present invention also provides methods for the treatment of excessive or undesirable permeability of a tissue by administering to a subject suffering from such a condition a composition comprising a peptide tight junction antagonist of the invention.Type: ApplicationFiled: October 20, 2008Publication date: March 31, 2011Applicant: Alba Therapeutics CorporationInventor: Amir Tamiz
-
Publication number: 20110077190Abstract: The present invention relates to compounds of Formula I, IA, II, HA, III, or IHA and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more caspases. Also described are methods where the compounds of Formula I, IA, II, IIA, III, or IIIA are used in the prevention and/or treatment of various diseases and conditions in subjects, including caspase-mediated diseases such as sepsis, myocardial infarction, ischemic stroke, spinal cord injury (SCI), traumatic brain injury (TBI) and neurodegenerative disease (e.g. multiple sclerosis (MS) and Alzheimer's, Parkinson's, and Huntington's diseases).Type: ApplicationFiled: May 21, 2009Publication date: March 31, 2011Inventors: Jan-Eric Ahlfors, Khalid Mekouar
-
Publication number: 20110064728Abstract: The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.Type: ApplicationFiled: June 28, 2010Publication date: March 17, 2011Inventors: Jian Chen, Ellen Filvaroff, Sherman Fong, Audrey Goddard, Paul Godowski, J. Christopher Grimaldi, Austin Gumey, Hanzhong Li, Kenneth Hillan, Sarah G. Hymowitz, Daniel Tumas, Melissa A. Starovasnik, Menno VanLookeren, Richard Vandlen, Colin Watanabe, P. Mickey Williams, William I. Wood, Daniel Yansura
-
Publication number: 20110061114Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO196, PRO217, PRO231, PRO236, PRO245, PRO246, PRO258, PRO287, PRO328, PRO344, PRO357, PRO526, PRO724, PRO731, PRO732, PRO1003, PRO1104, PRO1151, PRO1244, PRO1298, PRO1313, PRO1570, PRO1886, PRO1891, PRO4409, PRO5725, PRO5994, PRO6097, PRO7425, PRO10102, PRO10282, PRO61709 or PRO779 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.Type: ApplicationFiled: November 12, 2010Publication date: March 10, 2011Inventors: JOEL A. EDWARDS, Charles Montgomery, Zheng-Zheng Shi, Mary Jean Sparks
-
Publication number: 20110059885Abstract: The method of the invention relates to an OmCI polypeptide or a polynucleotide encoding an OmCI polypeptide for the treatment of a disease or condition mediated by a leukotriene or hydroxyeicosanoid.Type: ApplicationFiled: February 5, 2009Publication date: March 10, 2011Inventors: Susan Lea, Miles Nunn, Pietro Roversi
-
Publication number: 20110052729Abstract: The invention relates to a pharmaceutical or nutraceutical composition comprising an alkalized organic substance selected from the group comprising proteins, carbohydrates, lipids, amino acids, vitamins, therapeutic agents and mixtures thereof. Such compositions are useful for treating a range of diseases and conditions. They also give rise to beneficial physiological effects such as, for example, increasing physical strength, muscle mass and endurance.Type: ApplicationFiled: August 26, 2010Publication date: March 3, 2011Inventor: Jeffrey M. Golini
-
Publication number: 20110052616Abstract: The present invention concerns a peptide molecule or a nucleic acid molecule, for use in medicine and, in particular, for use in preventing or treating a non-cancerous condition or relieving pain in a patient. The invention also relates to a pharmaceutical composition comprising the peptide or nucleic acid molecule of the invention and methods of treatment thereof.Type: ApplicationFiled: February 25, 2009Publication date: March 3, 2011Applicant: Helperby Therapeutics LimitedInventors: Anthony Robert Milnes Coates, Yanira Riffo-Vasquez, Peter Tormay
-
Publication number: 20110038885Abstract: The present invention is directed to peptide analogs of chemokine, the pharmaceutically acceptable salts thereof, to methods of using such analogs to treat mammals and to pharmaceutical compositions useful therefor comprising said analogs.Type: ApplicationFiled: July 21, 2008Publication date: February 17, 2011Inventors: Zheng Xin Dong, Sun H. Kim
-
Publication number: 20110033521Abstract: Molecules and compositions including same for the isolation of MCP-1 and treatment of CCR2/MCP-1 associated diseases.Type: ApplicationFiled: April 10, 2006Publication date: February 10, 2011Applicant: Rappaport Family Institute for Research in the Medical SciencesInventors: Nathan Karin, Gizi Wildbaum, Yaniv Zohar, Liat Izhak, Uri Weinberg
-
Publication number: 20110027315Abstract: The present disclosure provides compositions comprising a protein cage and methods for using the protein cage compositions to induce an immune protection response, or to prevent or ameliorate a viral or a bacterial infection.Type: ApplicationFiled: September 5, 2008Publication date: February 3, 2011Inventors: Allen Harmsen, Trevor Douglas, Mark Young
-
Publication number: 20110014128Abstract: The present invention relates to a method for identifying a non-competitive peptide, which inhibits the activity of a cytokine receptor. This method includes the steps of selecting a candidate peptide containing from about 7 to about 20 amino acids derived from a flexible region of a cytokine receptor, and determining the ability of the peptide to inhibit or promote the oligomerization and/or activation of the receptor by measuring an activity of the receptor in the absence or the presence of the candidate peptide, wherein the non-competitive peptide is selected when the activity of the receptor is measurably lower in the presence of the peptide as compared to in the absence of the peptide so identified. This invention also provides agonists of cytokine receptor activity. Pharmaceutical compositions that comprise the identified peptides are disclosed.Type: ApplicationFiled: July 15, 2010Publication date: January 20, 2011Inventors: Sylvain Chemtob, Christiane Quiniou, Martin Beauchamp
-
Publication number: 20110008284Abstract: The present invention provides novel cyclosporin analogue compounds, pharmaceutical compositions comprising these compounds and methods of using these compounds for the treatment of disorders and diseases, including immune disorders, inflammatory disorders and viral infections.Type: ApplicationFiled: July 8, 2010Publication date: January 13, 2011Inventors: Xuri Gao, Yat Sun Or, Guoqiang Wang, Jiang Long
-
Publication number: 20110008251Abstract: The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Particular embodiments concern homodimers comprising monomers that contain a dimerization and docking domain attached to a precursor. The precursors may be virtually any molecule or structure, such as antibodies, antibody fragments, antibody analogs or mimetics, aptamers, binding peptides, fragments of binding proteins, known ligands for proteins or other molecules, enzymes, detectable labels or tags, therapeutic agents, toxins, pharmaceuticals, cytokines, interleukins, interferons, radioisotopes, proteins, peptides, peptide mimetics, polynucleotides, RNAi, oligosaccharides, natural or synthetic polymeric substances, nanoparticles, quantum dots, organic or inorganic compounds, etc. Other embodiments concern tetramers comprising a first and second homodimer, which may be identical or different.Type: ApplicationFiled: May 19, 2009Publication date: January 13, 2011Applicant: IBC PHARMACEUTICALS, INC.Inventors: Chien-Hsing Chang, David M. Goldenberg, William J. McBride, Edmund A. Rossi
-
Publication number: 20110008285Abstract: The present invention provides novel cyclosporin analogue compounds, pharmaceutical compositions comprising these compounds and methods of using these compounds for the treatment of disorders and diseases, including immune disorders, inflammatory disorders and viral infections.Type: ApplicationFiled: July 8, 2010Publication date: January 13, 2011Inventors: Jiang Long, Yat Sun Or, Xuri Gao, Guoqiang Wang
-
Publication number: 20110008269Abstract: Compositions and methods for the treatment of asthma and inflammatory ocular disorders are disclosed.Type: ApplicationFiled: August 9, 2010Publication date: January 13, 2011Inventor: Michael M. Grunstein
-
Publication number: 20110008286Abstract: The present invention provides novel proline substituted cyclosporinanalogue compounds, pharmaceutical compositions comprising these compounds and methods of using these compounds for the treatment of disorders and diseases, including immune disorders, inflammatory disorders and viral infections.Type: ApplicationFiled: July 8, 2010Publication date: January 13, 2011Inventors: Guoqiang Wang, Yat Sun Or, Jiang Long, Xuri Gao
-
Publication number: 20110002854Abstract: A pharmaceutical composition for treating or preventing a Th2-mediated disease or disorder includes live, killed or attentuated Franciscella tularensis or its components. The F. tularensis cells may be LVS cells. Administration of an effective amount may prevent or reduce bronchoconstriction or allergic airway inflammation through a T-helper cell (Th) 1-mediated suppression of an ongoing Th2 response mechanism.Type: ApplicationFiled: March 20, 2008Publication date: January 6, 2011Applicant: NATIONAL RESEARCH COUNCIL OF CANADAInventors: Wangxue Chen, Girishchandra Babubhai Patel
-
Publication number: 20100331237Abstract: A method is provided for introducing a GAG binding site into a protein comprising the steps: identifying a region in a protein which is not essential for structure maintenance introducing at least one basic amino acid into said site and/or deleting at least one bulky and/or acidic amino acid in said site, whereby said GAG binding site has a GAG binding affinity of Kd?10 ?M, preferably ?1 ?M, still preferred ?0.1 ?M, as well as modified GAG binding proteins.Type: ApplicationFiled: August 18, 2010Publication date: December 30, 2010Applicant: PROTAFFIN BIOTECHNOLOGIE AGInventor: Andreas J. KUNGL
-
Publication number: 20100331236Abstract: The invention relates to novel cyclic compounds which have the ability to modulate the activity of G protein-coupled receptors. The compounds preferably act as antagonists. In preferred embodiments, the invention provides cyclic peptidic and peptidomimetic antagonists of C5a receptors, which are active against C5a receptors on polymorphonuclear leukocytes and macrophages. The compounds of the invention are both potent and selective, and are useful in the treatment of a variety of inflammatory conditions.Type: ApplicationFiled: July 14, 2009Publication date: December 30, 2010Applicants: PROMICS PTY LIMITED, UNIQUEST PTY LIMITEDInventors: Stephen Maxwell Taylor, Ian Alexander Shiels, David Fairlie, Darren March, Michael Whitehouse
-
Publication number: 20100316628Abstract: The present invention relates to a novel method of preventing and/or treating respiratory disorders and respiratory-related complications in a subject by inhibiting the release of nitric oxide from basal cells in the respiratory tract.Type: ApplicationFiled: December 9, 2009Publication date: December 16, 2010Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: Sylvie Breton, Dennis Brown, Wai Chi Shum, Nicolas Da Silva
-
Publication number: 20100311644Abstract: A method of changing or otherwise converting the biological activity of a PKC peptide agonist to a peptide antagonist is described. The method involves substituting one or more amino acid residues so as to effect a change in charge in the peptide and/or to otherwise make the sequence similar to a sequence derived from the PKC binding site on the RACK protein for the respective PKC enzyme. Methods of inhibiting the activity of a PKC enzyme, and various peptide antagonists of ?PKC are also disclosed.Type: ApplicationFiled: May 24, 2010Publication date: December 9, 2010Inventor: Daria Mochly-Rosen
-
Publication number: 20100305024Abstract: The present invention provides a method of modulating calcineurin activity in a cell by contacting the cell with at least one ApoE analog. Methods of treating various disorders associated with calcineurin activity using one or more ApoE analogs are also disclosed. In particular, the present invention provides a method of reducing demyelination and promoting remyelination in a subject. Methods of treating spinal cord or nerve injury in a subject are also described.Type: ApplicationFiled: July 31, 2008Publication date: December 2, 2010Inventors: Michael P. Vitek, Feng-Qiao Li
-
Publication number: 20100279922Abstract: The present invention is directed to compounds according to formula, (R2R3)-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-R1, and pharmaceutically-acceptable salts thereof that act as ligands for one or more of the melanocortin receptors, to methods of using such compounds to treat mammals and to pharmaceutical compositions comprising said compounds.Type: ApplicationFiled: July 10, 2006Publication date: November 4, 2010Inventors: Zheng Xin Dong, Jacques-Pierre Moreau
-
Publication number: 20100267615Abstract: The present invention is directed to methods for treatment and/or prevention of a disease associated with vascular leak in a patient comprising administering to the patient an effective amount of SEQ ID NO: 1.Type: ApplicationFiled: June 3, 2010Publication date: October 21, 2010Applicant: FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBHInventors: Peter Petzelbauer, Rainer Henning, Sonja Reingruber, Waltraud Pasteiner, Marion Gröger
-
Publication number: 20100256043Abstract: The present invention is directed to the use of the peptide compound Glu-Ala-Leu-Glu-Leu-Ala-Arg-Gly-Ala-Ile-Phe-Gln-Ala-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Glu-Ala-Leu-Glu-Leu-Ala-Arg-Gly-Ala-Ile-Phe-Gln-Ala-NH2 optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.Type: ApplicationFiled: September 9, 2008Publication date: October 7, 2010Inventors: Dorian Bevec, Fabio Cavalli, Vera Cavalli, Gerald Bacher
-
Publication number: 20100249017Abstract: The present invention is directed to the use of the peptide compound Gly-Leu-Ser-Lys-Gly-Cys-Phe-Gly-Leu-Lys-Leu-Asp-Arg-Ile-Gly-Ser-Met-Ser-Gly-Leu-Gly-Cys-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquide buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Gly-Leu-Ser-Lys-Gly-Cys-Phe-Gly-Leu-Lys-Leu-Asp-Arg-Ile-Gly-Ser-Met-Ser-Gly-Leu-Gly-Cys-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.Type: ApplicationFiled: September 9, 2008Publication date: September 30, 2010Inventors: Dorian Bevec, Fabio Cavalli, Vera Cavalli, Gerald Bacher